Cargando…
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution
The success of targeted cancer therapy is limited by drug resistance that can result from tumor genetic heterogeneity. The current approach to address resistance typically involves initiating a new treatment after clinical/radiographic disease progression, ultimately resulting in futility in most pa...
Autores principales: | Jonsson, Vanessa D., Blakely, Collin M., Lin, Luping, Asthana, Saurabh, Matni, Nikolai, Olivas, Victor, Pazarentzos, Evangelos, Gubens, Matthew A., Bastian, Boris C., Taylor, Barry S., Doyle, John C., Bivona, Trever G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347024/ https://www.ncbi.nlm.nih.gov/pubmed/28287179 http://dx.doi.org/10.1038/srep44206 |
Ejemplares similares
-
Adaptive stress signaling in targeted therapy resistance in cancer
por: Pazarentzos, Evangelos, et al.
Publicado: (2015) -
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
por: Lin, Luping, et al.
Publicado: (2012) -
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Neel, Dana S., et al.
Publicado: (2017) -
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
por: Lara, Matthew S., et al.
Publicado: (2022) -
Rational Polytherapy with Antiepileptic Drugs
por: Lee, Jong Woo, et al.
Publicado: (2010)